EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk

Huberta E Hart, Olivier Kievits, Frans H Rutten, Monika H Hollander

Primary Care Diabetes · 2023

DOI: 10.1016/j.pcd.2023.02.001 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Primary Care Diabetes, 2023. Verfasst von Huberta E Hart und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, t…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: To evaluate whether the prescription of SGLT2-inhibitors in primary care patients with type 2 diabetes (T2DM) and a very high risk was according to the newest updated Dutch general practitioners' practice guidelines on T2DM. METHODS: This observational study with routine care data was conducted in a primary care setting in the Netherlands. The very high-risk population size was identified and analyzed via descriptive statistics. In this high-risk group the percentage of patients treated with SGLT2-inhibitors was assessed. RESULTS: Of the 1492 T2DM patients managed in primary care, 475 (31.8%) were classified as very high-risk based on (a history of) ischemic cardiovascular disease, chronic kidney disease, and/or heart failure. Of the very high-risk patients, 49 (10.3%) received SGLT2-inhibitors conform the guidelines. Of the remaining 426 high-risk patients 334 (70.3%) had no contraindication (eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesHumansHypoglycemic AgentsSodium-Glucose Transporter 2Risk FactorsHeart Disease Risk Factors

Stichwörter der Autor:innen

General practicePractice guidelinesPrimary care settingType 2 diabetesVery high-risk patients

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Leidsche Rijn Julius Healthcare Centers, Utrecht, the…
  • Leidsche Rijn Julius Healthcare Centers, Utrecht, the Netherlands.

Zitieren

APA

Hart, H. E., Kievits, O., Rutten, F. H., & Hollander, M. H. (2023). Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk. Primary Care Diabetes. https://doi.org/10.1016/j.pcd.2023.02.001

Vancouver

Hart HE, Kievits O, Rutten FH, Hollander MH. Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk. Primary Care Diabetes. 2023. doi:10.1016/j.pcd.2023.02.001

BibTeX
@article{Hart2023,
  author = {Hart, Huberta E and Kievits, Olivier and Rutten, Frans H and Hollander, Monika H},
  title = {Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk},
  journal = {Primary Care Diabetes},
  year = {2023},
  doi = {10.1016/j.pcd.2023.02.001}
}
Kostenlos starten →